Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 50, 2008, Pages 19579-19586

  Zhang, Huafeng ^a   Qian, David Z ^a   Tan, Yee Sun ^a   Lee, KangAe ^a   Gao, Ping ^a   Ren, Yunzhao R ^a   Rey, Sergio ^a   Hammers, Hans ^a   Chang, Daniel ^a   Pili, Roberto ^a   Dang, Chi V ^a   Liu, Jun O ^a   Semenza, Gregg L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Broadway Research Building ^*  (United States)

Author keywords

Cancer therapy; Hypoxia; Tumor xenograft

Indexed keywords

ACETYLDIGITOXIN; CARDIAC GLYCOSIDE; CONVALLATOXIN; CYCLOHEXIMIDE; CYMARIN; DIGOXIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NERIFOLIN; OUABAIN; PERIPLOCYMARIN; PERUVOSIDE; PROSCILLARIDIN; RAPAMYCIN; ROTENONE; STROPHANTHIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; FIREFLY LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG SCREENING; EXPERIMENTAL MOUSE; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TUMOR; TUMOR GENE; TUMOR RESISTANCE; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; DRUG ANTAGONISM; GENETICS; MOUSE MUTANT; PROTEIN SYNTHESIS; REPORTER GENE; TUMOR CELL LINE;

STROPHANTHUS GRATUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARDIAC GLYCOSIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DIGOXIN; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES, FIREFLY; MICE; MICE, SCID; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149374576     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0809763105     Document Type: Article

References (39)

1. Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J Cell Biochem 101:937-949.
2. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437.
3. Vaupel P, Mayer A (2007) Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239.
4. Manalo DJ, et al. (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-669.
5. Elvidge GP, et al. (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: The role of HIF-1α, HIF-2α, and other pathways. J Biol Chem 281:15215-15226.
6. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853-859.
7. Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15:678-685.
8. 2 tension. Proc Natl Acad Sci USA 92:5510-5514.
9. Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237.
10. Kaelin WG, Jr, Ratcliffe PJ (2008) Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30:393-402.
11. Maxwell PH, et al. (1999) The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
12. Garcia JA (2006) HIFing the brakes: Therapeutic opportunities for treatment of human malignancies. Sci STKE 2006(337):pe25.
13. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430.
14. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004.
15. Thomas GV, et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127.
16. Zhong H, et al. (1999) Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59:5830-5835.
17. Talks KL, et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421.
18. Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26:341-352.
19. Semenza GL, et al. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271:32529-32537.
20. 2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25:207-217.
21. Chong CR, et al. (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2:263-270.
22. Agani FH, Pichiule P, Chavez JC, LaManna JC (2002) Inhibitors of mitochondrial complex I attenuate the accumulation of hypoxia-inducible factor-1 during hypoxia in Hep3B cells. Comp Biochem Physiol A 132:107-109.
23. Epstein AC, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54.
24. Arsham AM, Howell JJ, Simon MC (2003) A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278:29655-29660.
25. Al-Ghoul M, Valdes R, Jr (2008) Mammalian cardenolides in cancer prevention and therapeutics. Ther Drug Monit 30:234-238.
26. Bielawski K, Winnicka K, Bielawska A (2006) Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29:1493-1497.
27. Rapisarda A, et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316-4324.
28. Creighton-Gutteridge M, et al. (2007) Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1α protein accumulation by NSC 644221. Clin Cancer Res 13:1010-1018.
29. Gao P, et al. (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12:230-238.
30. Mijatovic T, et al. (2007) Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 1776:32-57.
31. Newman RA, Yang P, Pawlus AD, Block KI (2008) Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8:36-49.
32. Stenkvist B (1999) Is digitalis a therapy for breast carcinoma? Oncol Rep 6:493-496.
33. Haux J, Klepp O, Spigset O, Tretli S (2001) Digitoxin medication and cancer; Case control and internal dose-response studies. BMC Cancer 1:11.
34. Inada A, et al. (1993) Anti-tumor promoting activities of natural products. II. Inhibitory effects of digitoxin on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors. Biol Pharm Bull 16:930-931.
35. Svensson A, Azarbayjani F, Bäckman U, Matsumoto T, Christofferson R (2005) Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res 25:207-212.
36. Mijatovic T, et al. (2006) The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non small cell lung cancer cells. Mol Cancer Ther 5:391-399.
37. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441.
38. Giatromanolaki A, et al. (2004) c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1α dependent. Clin Cancer Res 10:7972-7977.
39. Swinson DE, et al. (2004) Hypoxia-inducible factor-1α in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int J Cancer111:43-50.